WallStreetZenWallStreetZen

NASDAQ: CTNM
Contineum Therapeutics Inc Stock Ownership - Who owns Contineum Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Contineum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Daniel S. LorrainChief Scientific Officer2024-11-251,010$16.02
$16.18kSell
Daniel S. LorrainChief Scientific Officer2024-11-1899$17.05
$1.69kSell
Daniel S. LorrainChief Scientific Officer2024-11-186,091$16.37
$99.73kSell

1 of 1

CTNM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CTNM insiders and whales buy or sell their stock.

CTNM Shareholders

What type of owners hold Contineum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Johnson Johnson7.06%1,979,173$19.67MInstitution
Johnson Johnson7.06%1,979,173$19.67MInsider
Suvretta Capital Management LLC6.13%1,720,000$17.10MInstitution
Franklin Resources Inc6.06%1,698,825$16.89MInstitution
Fmr LLC3.01%843,150$8.38MInstitution
Sectoral Asset Management Inc2.86%800,787$7.96MInstitution
Vanguard Group Inc2.65%744,001$7.40MInstitution
Perceptive Advisors LLC2.49%699,486$6.95MInstitution
Hhlr Advisors Ltd2.39%669,337$6.65MInstitution
Red Tree Management LLC2.28%638,158$6.34MInstitution

1 of 3

CTNM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CTNM49.41%9.63%Net Selling
VNDA52.49%47.51%Net SellingNet Buying
VOR45.02%48.14%Net Selling
LCTX39.05%60.95%Net Buying
DBVT5.28%26.94%Net SellingNet Selling
View Top Biotech Stocks

Contineum Therapeutics Stock Ownership FAQ

Who owns Contineum Therapeutics?

Contineum Therapeutics (NASDAQ: CTNM) is owned by 49.41% institutional shareholders, 9.63% Contineum Therapeutics insiders, and 40.96% retail investors. Johnson Johnson is the largest individual Contineum Therapeutics shareholder, owning 1.98M shares representing 7.06% of the company. Johnson Johnson's Contineum Therapeutics shares are currently valued at $19.67M.

If you're new to stock investing, here's how to buy Contineum Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.